738 related articles for article (PubMed ID: 12716275)
1. Depression-free days as a summary measure of the temporal pattern of response and remission in the treatment of major depression: a comparison of venlafaxine, selective serotonin reuptake inhibitors, and placebo.
Mallick R; Chen J; Entsuah AR; Schatzberg AF
J Clin Psychiatry; 2003 Mar; 64(3):321-30. PubMed ID: 12716275
[TBL] [Abstract][Full Text] [Related]
2. Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression.
Stahl SM; Entsuah R; Rudolph RL
Biol Psychiatry; 2002 Dec; 52(12):1166-74. PubMed ID: 12488062
[TBL] [Abstract][Full Text] [Related]
3. Two items on the Hamilton Depression rating scale are effective predictors of remission: comparison of selective serotonin reuptake inhibitors with the combined serotonin/norepinephrine reuptake inhibitor, venlafaxine.
Silverstone PH; Entsuah R; Hackett D
Int Clin Psychopharmacol; 2002 Nov; 17(6):273-80. PubMed ID: 12409680
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder.
Silverstone PH; Salinas E
J Clin Psychiatry; 2001 Jul; 62(7):523-9. PubMed ID: 11488362
[TBL] [Abstract][Full Text] [Related]
5. Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.
Lenox-Smith AJ; Jiang Q
Int Clin Psychopharmacol; 2008 May; 23(3):113-9. PubMed ID: 18408525
[TBL] [Abstract][Full Text] [Related]
6. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo.
Entsuah AR; Huang H; Thase ME
J Clin Psychiatry; 2001 Nov; 62(11):869-77. PubMed ID: 11775046
[TBL] [Abstract][Full Text] [Related]
7. Randomized, double-blind comparison of venlafaxine and sertraline in outpatients with major depressive disorder. Venlafaxine 631 Study Group.
Mehtonen OP; Søgaard J; Roponen P; Behnke K
J Clin Psychiatry; 2000 Feb; 61(2):95-100. PubMed ID: 10732656
[TBL] [Abstract][Full Text] [Related]
8. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease.
Richard IH; McDermott MP; Kurlan R; Lyness JM; Como PG; Pearson N; Factor SA; Juncos J; Serrano Ramos C; Brodsky M; Manning C; Marsh L; Shulman L; Fernandez HH; Black KJ; Panisset M; Christine CW; Jiang W; Singer C; Horn S; Pfeiffer R; Rottenberg D; Slevin J; Elmer L; Press D; Hyson HC; McDonald W;
Neurology; 2012 Apr; 78(16):1229-36. PubMed ID: 22496199
[TBL] [Abstract][Full Text] [Related]
9. Venlafaxine XR demonstrates higher rates of sustained remission compared to fluoxetine, paroxetine or placebo.
Shelton C; Entsuah R; Padmanabhan SK; Vinall PE
Int Clin Psychopharmacol; 2005 Jul; 20(4):233-8. PubMed ID: 15933485
[TBL] [Abstract][Full Text] [Related]
10. Venlafaxine extended-release: a review of its use in the management of major depression.
Wellington K; Perry CM
CNS Drugs; 2001; 15(8):643-69. PubMed ID: 11524036
[TBL] [Abstract][Full Text] [Related]
11. Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trial.
Davidson J; Baldwin D; Stein DJ; Kuper E; Benattia I; Ahmed S; Pedersen R; Musgnung J
Arch Gen Psychiatry; 2006 Oct; 63(10):1158-65. PubMed ID: 17015818
[TBL] [Abstract][Full Text] [Related]
12. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors.
Thase ME; Entsuah AR; Rudolph RL
Br J Psychiatry; 2001 Mar; 178():234-41. PubMed ID: 11230034
[TBL] [Abstract][Full Text] [Related]
13. Venlafaxine extended release in the short-term treatment of depressed and anxious primary care patients with multisomatoform disorder.
Kroenke K; Messina N; Benattia I; Graepel J; Musgnung J
J Clin Psychiatry; 2006 Jan; 67(1):72-80. PubMed ID: 16426091
[TBL] [Abstract][Full Text] [Related]
14. Randomized, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression.
Costa e Silva J
J Clin Psychiatry; 1998 Jul; 59(7):352-7. PubMed ID: 9714263
[TBL] [Abstract][Full Text] [Related]
15. Once- versus twice-daily venlafaxine therapy in major depression: a randomized, double-blind study.
Amsterdam JD; Hooper MB; Amchin J
J Clin Psychiatry; 1998 May; 59(5):236-40. PubMed ID: 9632034
[TBL] [Abstract][Full Text] [Related]
16. Placebo-controlled inpatient comparison of venlafaxine and fluoxetine for the treatment of major depression with melancholic features.
Sheehan DV; Nemeroff CB; Thase ME; Entsuah R;
Int Clin Psychopharmacol; 2009 Mar; 24(2):61-86. PubMed ID: 19238088
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of venlafaxine in patients with major depressive disorder who have unsustained or no response to selective serotonin reuptake inhibitors: an open-label, uncontrolled study.
Kaplan EM
Clin Ther; 2002 Jul; 24(7):1194-200. PubMed ID: 12182262
[TBL] [Abstract][Full Text] [Related]
18. Venlafaxine versus fluvoxamine in the treatment of delusional depression: a pilot double-blind controlled study.
Zanardi R; Franchini L; Serretti A; Perez J; Smeraldi E
J Clin Psychiatry; 2000 Jan; 61(1):26-9. PubMed ID: 10695642
[TBL] [Abstract][Full Text] [Related]
19. A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression.
Schatzberg A; Roose S
Am J Geriatr Psychiatry; 2006 Apr; 14(4):361-70. PubMed ID: 16582045
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder.
Trivedi MH; Pigotti TA; Perera P; Dillingham KE; Carfagno ML; Pitts CD
J Clin Psychiatry; 2004 Oct; 65(10):1356-64. PubMed ID: 15491239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
